

## **Synonym**

Leucine-rich repeat-containing protein 15,LRRC15,LIB,hLib

#### Source

Human LRRC15 Protein, His Tag(LR5-H51H3) is expressed from CHO cells. It contains AA Tyr 22 - Gly 538 (Accession # Q8TF66-1).

Predicted N-terminus: Tyr 22

#### **Molecular Characterization**

LRRC15(Tyr 22 - Gly 538) Q8TF66-1

Poly-his

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 59.7 kDa. The protein migrates as 55-65 kDa when calibrated against <u>Star Ribbon Pre-stained Protein Marker</u> under reducing (R) condition (SDS-PAGE) due to glycosylation.

### Endotoxin

Less than 1.0 EU per µg by the LAL method.

## **Purity**

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

## **Formulation**

Lyophilized from  $0.22~\mu m$  filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

#### Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

#### **Storage**


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.


### **SDS-PAGE**



Human LRRC15 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With <u>Star Ribbon Pre-stained Protein Marker</u>).

### **Bioactivity-ELISA**

#### **SEC-MALS**




The purity of Human LRRC15 Protein, His Tag (Cat. No. LR5-H51H3) is more than 90% and the molecular weight of this protein is around 55-85 kDa verified by SEC-MALS.

Report

# **Human LRRC15 / LIB Protein, His Tag (MALS verified)**







Immobilized Human LRRC15 Protein, His Tag (Cat. No. LR5-H51H3) at 2  $\mu$ g/mL (100  $\mu$ L/well) can bind Samrotamab with a linear range of 0.4-13 ng/mL (QC tested).

# Background

LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.

# **Clinical and Translational Updates**

